Oncogenic KRAS Rewires mRNA Stability and Translation through AGO2-Mediated Disruption of the miRNA pathway.
KRAS mutations occur in over 90% of pancreatic ductal adenocarcinomas (PDACs). Despite recent advances in targeting oncogenic KRAS, tumors eventually acquire resistance. A more comprehensive understanding of the mechanisms connecting KRAS signaling to tumor progression could facilitate the development of effective ther...